NCT02388048 2025-01-29Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic LeukemiaGruppo Italiano Malattie EMatologiche dell'AdultoPhase 2 Completed19 enrolled